716 related articles for article (PubMed ID: 24086952)
21. Future agents and treatment directions in multiple myeloma.
Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
[TBL] [Abstract][Full Text] [Related]
23. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
24. Practical Approaches to the Management of Dual Refractory Multiple Myeloma.
Lee HC; Mark TM; Shah JJ
Curr Hematol Malig Rep; 2016 Apr; 11(2):148-55. PubMed ID: 26898556
[TBL] [Abstract][Full Text] [Related]
25. Novel agents in the treatment of multiple myeloma: a review about the future.
Naymagon L; Abdul-Hay M
J Hematol Oncol; 2016 Jun; 9(1):52. PubMed ID: 27363832
[TBL] [Abstract][Full Text] [Related]
26. An update in treatment options for multiple myeloma in nontransplant eligible patients.
Broijl A; Sonneveld P
Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies in myeloma.
Sondergeld P; van de Donk NW; Richardson PG; Plesner T
Clin Adv Hematol Oncol; 2015 Sep; 13(9):599-609. PubMed ID: 26452191
[TBL] [Abstract][Full Text] [Related]
28. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
29. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Relapsed/Refractory Multiple Myeloma.
Neri P; Bahlis NJ; Paba-Prada C; Richardson P
Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic potential of microbial proteasome inhibitors.
Momose I; Kawada M
Int Immunopharmacol; 2016 Aug; 37():23-30. PubMed ID: 26589840
[TBL] [Abstract][Full Text] [Related]
32. Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.
Grosicki S; Barchnicka A
Expert Rev Hematol; 2016 Jul; 9(7):621-8. PubMed ID: 27322214
[TBL] [Abstract][Full Text] [Related]
33. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Xia C; Ribeiro M; Scott S; Lonial S
Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
[TBL] [Abstract][Full Text] [Related]
34. [Novel agents in multiple myeloma treatment].
Ito S
Rinsho Ketsueki; 2015 Oct; 56(10):2066-73. PubMed ID: 26458446
[TBL] [Abstract][Full Text] [Related]
35. Novel therapeutic strategies for multiple myeloma.
Mimura N; Hideshima T; Anderson KC
Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
[TBL] [Abstract][Full Text] [Related]
36. Multiple myeloma: new uses for available agents, excitement for the future.
Anderson KC
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):694-6. PubMed ID: 25995433
[TBL] [Abstract][Full Text] [Related]
37. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
38. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
Lee HC; Weber DM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
[TBL] [Abstract][Full Text] [Related]
39. Research progress in proteasome inhibitor resistance to multiple myeloma.
Wu J; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):900-908. PubMed ID: 34565737
[TBL] [Abstract][Full Text] [Related]
40. [Multiple myeloma and other plasma cell dyscrasias].
Nagy Z
Magy Onkol; 2016 Jun; 60(2):154-63. PubMed ID: 27275642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
